Lucira Health (LHDX) Stock Soared 15.21% At Premarket Trading. Here’s What Happened

Lucira Health, Inc. (LHDX), a biotechnology company specializing in the production and expansion of lucrative infectious disease test kits, notified it can efficiently distinguish the “double mutant” variant of COVID-19 with its molecular test kit. LHDX stock price saw a 15.21% gain following the news.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The “double mutant” variant was initially found in India on March 24, 2021. CDC is tracing both of its genetic mutation sequences, which is the first variant to have two mutations sequences out of its kind.

Lucira’s ‘swab, stir and detect’ testing method had a 100% success in being performed in less than a two-minute time frame. Time taken for the present main laboratory testing can take upto two weeks to produce results with the same accuracy ratio, withLucira’s testing kit results being produced on spot.

Now What.

Lucira Health’s testing kit was the pioneer in FDA-authorized, diagnostic test for different variants of Corona strain, that could be handled through users at remote or any room with adequate conditions.

Lucira Health Chief Technology Officer and co-founder Debkishore, Dr Mitra added,

“Since we began this monitoring, our Lucira test kit has been reactive to more than 99.9% of available COVID-19 viral sequences, which are roughly 30,000 letters long. It’s complex work, but really important since users rely on our test for accurate results” establishing the accuracy and efficiency of LHDX product.

Lucira has also concluded an additional Community Testing study among asymptomatic Covid-19 patients targeting molecular amplification for enhanced accuracy in their product.


LHDX has been for Covid19 associated diagnostic tests and is keen on its mission for expansion. Furthermore, reducing testing time rate as well as upgrading accuracy and providing portability and ease in testing has risen investor interest, especially amidst the time of a pandemic.

Most Popular